Phase 2 Trial Data Reveals Promising Response Rates for NBTXR3 in Lung Cancer
Nanobiotix has announced the presentation of Part 1 data from its randomized Phase 2 CONVERGE trial testing JNJ-1900 (NBTXR3), a first-in-class nanoradioenhancer, in patients with stage 3 inoperable non-small cell lung cancer (NSCLC) at the 2026 ESTRO Annual Meeting. Backed by Johnson & Johnson, these early results signal a potentially significant advance in lung cancer therapeutics.
Standout Results: Response Rates Far Surpass Status Quo
Among the first 7 patients who completed the full regimen—which included concurrent chemoradiotherapy, one-time intratumoral injection of NBTXR3, and durvalumab consolidation—the trial observed an overall response rate (ORR) of 85.7%. Even more notably, the complete response rate (CRR) stood at 57.1% (4 out of 7 patients), with all 7 maintaining disease control (DCR 100.0%). By comparison, standard care options see complete response rates below 5% in this population, underscoring the magnitude of these results.
| Efficacy Metric | NBTXR3 (JNJ-1900) Regimen | Typical Standard of Care |
|---|---|---|
| Overall Response Rate (ORR) | 85.7% | ~30–50% |
| Complete Response Rate (CRR) | 57.1% | <5% |
| Disease Control Rate (DCR) | 100.0% | ~40–60% |
Early Indications of Safety and Long-Term Benefit
The initial findings suggest that NBTXR3 delivery is both feasible and safe in the stage III inoperable NSCLC setting. Notably, all patients avoided disease progression and some exhibited deepening responses over time, opening the door for durable benefits not typically seen with current therapies. Researchers highlighted the potential for NBTXR3 to be scalable across various tumor types and compatible with multiple therapy combinations, due to its physics-based mechanism of action.
JNJ-1900 (NBTXR3): Innovative Nanoparticle Meets Radiotherapy
NBTXR3 consists of functionalized hafnium oxide nanoparticles, administered via a single intratumoral injection and activated by standard radiotherapy. This triggers significant tumor cell death, followed by an adaptive immune response. The therapy is already being evaluated in a global Phase 3 trial for head and neck cancers and benefits from a Fast Track designation by the FDA for locally advanced HNSCC in patients ineligible for platinum-based chemotherapy.
Broader Implications: A Possible New Standard for Unresectable Stage 3 NSCLC?
With these preliminary results, Nanobiotix and its research partners suggest that NBTXR3 could redefine treatment expectations for stage 3 inoperable NSCLC—a notoriously difficult-to-treat population. The absence of progression and high rates of deep response hint at long-term promise, though larger studies will be needed to confirm these benefits as the trial progresses.
Key Contacts for Stakeholders
| Department | Contact Name | Phone/Email |
|---|---|---|
| Communications | Brandon Owens, VP | +1 (617) 852-4835 contact@nanobiotix.com |
| Investor Relations (US) | Joanne Choi, VP | +1 (713) 609-3150 joanne.choi@nanobiotix.com |
| Investor Relations (EU) | Ricky Bhajun, Director | +33 (0) 79 97 29 99 investors@nanobiotix.com |
Takeaway: Early Signals Point to Transformative Potential
While early-stage data should always be interpreted with some caution, the magnitude of response in this high-need population puts NBTXR3 in the scientific spotlight. If these results hold in larger cohorts, NBTXR3 could significantly influence future lung cancer treatment algorithms. Investors and clinicians alike will be watching for updates as the CONVERGE study moves forward.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI